Detalhe da pesquisa
1.
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.
Blood
; 142(7): 621-628, 2023 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37319432
2.
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.
Cancer
; 130(9): 1663-1672, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38127583
3.
Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.
Br J Haematol
; 204(5): 1944-1952, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38448009
4.
Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts.
Am J Hematol
; 99(2): 245-253, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38100199
5.
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study.
Am J Hematol
; 99(4): 562-569, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38314663
6.
Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant.
Br J Haematol
; 202(4): 866-873, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37376789
7.
Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant.
Br J Haematol
; 200(1): 35-44, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36068929
8.
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
N Engl J Med
; 382(6): 545-553, 2020 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32023374
9.
CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy.
Histopathology
; 83(1): 143-148, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36994939
10.
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
Haematologica
; 108(1): 98-109, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35833303
11.
Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant.
BMC Cancer
; 23(1): 1258, 2023 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38124057
12.
NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022.
J Natl Compr Canc Netw
; 21(2): 108-115, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36791762
13.
Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience.
Am J Hematol
; 98(10): 1571-1578, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37461327
14.
Methylene blue for intractable pain from oral mucositis related to cancer treatment: a randomized phase 2 clinical trial.
BMC Med
; 20(1): 377, 2022 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36324139
15.
Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis.
Haematologica
; 107(4): 899-908, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33951890
16.
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States.
Cancer
; 127(1): 82-92, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966625
17.
Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis.
Br J Haematol
; 192(3): 560-567, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33517581
18.
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.
Blood
; 134(1): 22-29, 2019 07 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30952672
19.
Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia.
Acta Haematol
; 144(1): 74-81, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-32604096
20.
Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial.
Biol Blood Marrow Transplant
; 26(8): 1439-1445, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32438043